Patents by Inventor David E. Steinmeyer

David E. Steinmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
    Patent number: 8148331
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: April 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Anurag S. Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson
  • PLATFORM ANTIBODY COMPOSITIONS
    Publication number: 20110027262
    Abstract: The present invention provides novel compositions of human IgG2 antibodies comprising a chelating agent. The present invention also provides novel antibody compositions that exhibit improved chemical and/or physical stability. Also provided are methods of treating diseases and conditions with compositions of human IgG2 antibodies, including inflammatory diseases and neoplasia disorders.
    Type: Application
    Filed: September 10, 2010
    Publication date: February 3, 2011
    Inventors: Tapan Das, Kevin King, Nema Sandeep, Singh Satish, David E. Steinmeyer, David Zeng
  • Method for the Preparation of Growth Hormone and Antagonist Thereof Having Lower Levels of Isoform Impurities Thereof
    Publication number: 20100021966
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Application
    Filed: March 17, 2009
    Publication date: January 28, 2010
    Inventors: Anurag Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson
  • Process for decreasing aggregate levels of pegylated protein
    Patent number: 7470779
    Abstract: The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. The method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: December 30, 2008
    Assignee: Pfizer Inc.
    Inventors: Denis M. Boyle, John J. Buckley, Gary V. Johnson, David E. Steinmeyer, Michele Toal, Serdar Aykent, Anurag S. Rathore
  • Platform Antibody Compositions
    Publication number: 20080248047
    Abstract: The present invention provides novel compositions of human IgG2 antibodies comprising a chelating agent. The present invention also provides novel antibody compositions that exhibit improved chemical and/or physical stability. Also provided are methods of treating diseases and conditions with compositions of human IgG2 antibodies, including inflammatory diseases and neoplasia disorders.
    Type: Application
    Filed: March 2, 2006
    Publication date: October 9, 2008
    Inventors: Tapan Das, Kevin King, Nema Sandeep, Singh Satish, David E. Steinmeyer, David Zeng
  • Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
    Publication number: 20040048315
    Abstract: The present invention is directed generally to recombinant methods for making a desired polypeptide. These method(s) yield a polypeptide product containing reduced levels of isoform impurities thereof. In particular, the present invention is directed to (1) a recombinant method for preparing growth hormone with reduced isoform impurities thereof and (2) a recombinant method for preparing a growth hormone antagonist, such as pegvisomant, and its protein intermediate, also having reduced isoform impurities thereof. More specifically, the isoform impurities that are decreased by methods of the present invention are the trisulfide and des-phe isoform impurities of growth hormone and growth hormone antagonist (or its intermediate), respectively.
    Type: Application
    Filed: August 25, 2003
    Publication date: March 11, 2004
    Applicant: Pharmacia Corporation
    Inventors: Anurag Rathore, Stephen B. Lyle, David E. Steinmeyer, Scott I. Allen, John Meyer, Denis M. Boyle, John J. Buckley, Gary V. Johnson